Bello Bio

Bello Biotherapeutics is a biotechnology company focused on the discovery and development of molecular glues, a novel class of small molecule therapeutics designed to induce the degradation of disease-causing proteins. By leveraging a proprietary platform that integrates structural biology, high-throughput screening, and computational modeling, the company aims to target "undruggable" proteins, including transcription factors and other drivers of cancer and inflammatory diseases. Founded by pioneers in the field of targeted protein degradation from the Dana-Farber Cancer Institute, Bello is expanding the scope of E3 ligase recruitment beyond traditional pathways. The company is backed by prominent life science investors and is currently advancing a pipeline of pre-clinical programs. Its approach represents a significant advancement in the field of targeted protein degradation, seeking to unlock new therapeutic modalities for high-unmet-need indications.